Institution
Atlantic Health System
Healthcare•Morristown, New Jersey, United States•
About: Atlantic Health System is a healthcare organization based out in Morristown, New Jersey, United States. It is known for research contribution in the topics: Catheter ablation & Antiarrhythmic agent. The organization has 277 authors who have published 299 publications receiving 6594 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The payment models described in this review offer an opportunity to create more satisfying approaches to patient care while improving value and have potential to support more effective coordination and to facilitate broader health care system transformation.
Abstract: Importance The US health care system faces an unsustainable trajectory of high costs and inconsistent outcomes. The fee-for-service payment model has contributed to inefficiency, and new payment methods are a promising approach to improving value. Health reforms are needed to increase patient access, reduce costs, and improve health care quality, and the landmark Medicare Access and CHIP Reauthorization Act presents a roadmap for reform. The product of a collaboration between primary care and cardiology clinicians, this review describes a conceptual approach to delivery and payment reforms that aim to better support primary care-cardiology comanagement of chronic cardiovascular disease (CVD). Observations Few existing alternative payment models specifically address long-term management of CVD. Primary care medical homes and accountable care organizations come closest, but both emphasize primary care, and cardiologists have often not been well engaged. A collaborative care framework should articulate distinct roles and responsibilities for primary care and cardiology in CVD comanagement. Finally, a series of payment models aim to better support clinicians in providing accountable, seamless, and patient-centered cardiac care. Conclusions & relevance Clinical leadership is essential during this time of change in the health care system. Patients often struggle to navigate a fragmented and expensive system, whereas clinicians often practice with incomplete information about tests, treatments, and recommendations by their colleagues. The payment models described in this review offer an opportunity to create more satisfying approaches to patient care while improving value. These models have potential to support more effective coordination and to facilitate broader health care system transformation.
10 citations
••
TL;DR: Two fairly large studies add to the already extensive body of evidence that the overwhelming proportion of cases of vasa previa can be diagnosed prenatally and that this diagnosis and planned cesarean delivery before labor lead to almost universally excellent outcomes.
10 citations
••
TL;DR: Glycemic control is a modifiable target to improve morbidity and mortality in patients with advanced cirrhosis and when combined with elderly age is associated with increased risk of inpatient mortality.
9 citations
••
TL;DR: This work sought to understand how the emergence of VN resistant microbes has changed the antibiotic management of children's febrile neutropenic FN.
Abstract: Purpose
The increasing frequency of Gm+ infections in febrile neutropenic (FN) patients has resulted in increased use of vancomycin (VN). Likely as a result, VN-resistant Enterococcus (VRE) has become a significant concern in FN patients. We sought to understand how the emergence of VN resistant microbes has changed the antibiotic management of pediatric FN.
Methods
A questionnaire was distributed by e-mail to responsible investigators of the Children's Oncology Group.
Results
One hundred and thirty responses were analyzed. Forty-four percent initially used monotherapy, with 82% of those using ceftazidime. Twenty-seven used VN with another agent, generally ceftazidime. After the emergence of VRE and VN-resistant staphylococcus (VRS), monotherapy increased to 58%. Ceftazidime continued to be most frequently used. There was a 57% reduction in the use of VN with 88% of centers not currently using VN in their initial treatment of FN. Forty-seven percent of the centers that continue to use VN have VRE, while 90% that have discontinued its use have VRE/VRS.
Conclusions
Ours is the first study to survey current practices in the treatment of pediatric FN and to document changes in practice patterns due to emerging antibiotic resistance patterns. We demonstrate increased use of monotherapy for FN, and a 57% decrease in the use of VN. Local considerations influence antibiotic choices with a significant difference in VRE prevalence between those centers that continue to use VN as compared to those that have discontinued it. © 2004 Wiley-Liss, Inc.
9 citations
••
The Royal Marsden NHS Foundation Trust1, University of Louisville2, University of Pittsburgh3, University of Colorado Boulder4, Yale University5, University of Florida Health6, University of Minnesota7, University of Szeged8, Atlantic Health System9, University of Navarra10, Cambridge University Hospitals NHS Foundation Trust11, Mount Sinai Hospital12
TL;DR: Lifileucel may offer a better clinical outcome when used earlier upon detection of progression on prior anti-PD-1 rather than retreatment with anti- PD-1 based regimens.
Abstract: 9505Background: Immune checkpoint inhibitors (ICI) have become standard of care for treatment of metastatic melanoma. Most patients with advanced melanoma progress on ICI and treatment options are ...
9 citations
Authors
Showing all 279 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kurt A. Jaeckle | 57 | 169 | 14597 |
Donald E. Casey | 56 | 102 | 62844 |
Sanjeev Saksena | 44 | 169 | 6463 |
John J. Halperin | 42 | 145 | 9806 |
Linda D. Gillam | 39 | 102 | 9249 |
Missak Haigentz | 39 | 129 | 4217 |
Ian J. Griffin | 35 | 107 | 3998 |
Philip T. Levy | 30 | 106 | 6823 |
Patrick J. Culligan | 29 | 72 | 2962 |
Joel R. Rosh | 27 | 92 | 5189 |
Michael L. Gruber | 24 | 45 | 4877 |
Linda D. Gillam | 20 | 61 | 1895 |
Eric D. Whitman | 19 | 48 | 2576 |
Elizabeth A. Eckman | 19 | 33 | 3743 |
Brian M. Slomovitz | 16 | 75 | 1595 |